Literature DB >> 1686064

Bufuralol, dextromethorphan, and debrisoquine as prototype substrates for human P450IID6.

T Kronbach.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1686064     DOI: 10.1016/0076-6879(91)06120-r

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


× No keyword cloud information.
  6 in total

1.  Synthetic strategies to lower affinity for CYP2D6.

Authors:  R C Halliday; B C Jones; B K Park; D A Smith
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Oct-Dec       Impact factor: 2.441

2.  Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions.

Authors:  C Prakash; A Kamel; D Cui; R D Whalen; J J Miceli; D Tweedie
Journal:  Br J Clin Pharmacol       Date:  2000       Impact factor: 4.335

3.  Toward a systems approach to the human cytochrome P450 ensemble: interactions between CYP2D6 and CYP2E1 and their functional consequences.

Authors:  Dmitri R Davydov; Nadezhda Y Davydova; John T Rodgers; Thomas H Rushmore; Jeffrey P Jones
Journal:  Biochem J       Date:  2017-10-10       Impact factor: 3.857

4.  An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems.

Authors:  R C Halliday; B C Jones; D A Smith; N R Kitteringham; B K Park
Journal:  Br J Clin Pharmacol       Date:  1995-10       Impact factor: 4.335

Review 5.  Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.

Authors:  Ulrich M Zanger; Sebastian Raimundo; Michel Eichelbaum
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-15       Impact factor: 3.000

6.  The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction.

Authors:  Hiromi Okabe; Miyako Hasunuma; Yukiya Hashimoto
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.200

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.